News

Susan Bal, MD, discussed GPRC5D as an immunotherapeutic target in multiple myeloma and findings from a phase 1 study evaluating a novel CAR T-cell therapy working to target GPRC5D.

From bispecific antibodies transforming B-cell lymphoma treatment to immunotherapy breakthroughs in breast cancer and gene therapy innovations for hematologic malignancies, recent advancements offer hope.

Matthew Matasar, MD, discusses how ibrutinib given in combination with venetoclax compares with ibrutinib and placebo for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Ariel Lopez-Chavez, MD, provided insights into the current landscape of small cell lung cancer treatment, highlighting approved options and ongoing research.

Identifying differences in pancreatic cancer subtypes could be at the center of developing targeted treatments in this challenging disease.

Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.

Robert Dreicer, MD, MS, MACP, FASCO, discusses the limitations of using prostate-specific antigen levels alone to guide prostate cancer treatment.

Scott T. Tagawa, MD, MS, FACP, FASCO, highlights a key difference between oral androgen receptor inhibitor drugs and therapeutic radionuclides for the treatment of prostate cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses that patients with advanced prostate cancer benefit from a multidisciplinary care team.

Adam D. Cohen, MD, discusses the new era of multiple myeloma treatment with bispecifics and CAR T-cell therapy.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.

Raajit K. Rampal, MD, PhD, discusses the established role of JAK inhibition for the treatment of myelofibrosis.

Jeff Auletta, MD, discusses findings from a study evaluationg posttransplant cyclophosphamide in unmatched stem cell transplants.

Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.

Samilia Obeng-Gyasi, MD, MPH, delved into the background and findings of this study assessing the correlation between neighborhood opportunity, allostatic load, and all-cause mortality among patients with breast cancer.

The combination of zanubrutinib and obinutuzumab is now an approved treatment option for adult patients with relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.

Hatem Soliman, MD, highlights the crucial role of HER2 targeting and staying informed about evolving treatment options for better patient outcomes in the HER2-positive breast cancer space.

In a matched indirect comparison of zanubrutinib vs acalabrutinib, the former showed survival and response improvements in patients with chronic lymphocytic leukemia.

Nivolumab given with cisplatin-based chemotherapy has received approval from the FDA for patients with treatment-naive unresectable or mUC.

The combination of a novel mTORC1/2 inhibitor with paclitaxel could present a new way of targeting metastatic or persistent endometrial cancer.

Belantamab mafodotin plus pomalidomide and dexamethasone significantly extended progression-free survival in multiple myeloma, offering a potential new treatment option with different mechanisms of action.

Cambritaxestat, a first-in-class therapy in development for highly fibrotic cancer indications that overexpress autotaxin, has been granted an orphan drug designation from the FDA in pancreatic cancer.

In an interview with Targeted Oncology, Raajit K. Rampal, MD, PhD, provided an update on developments, unmet needs, and future directions for the treatment of patients with myelofibrosis.

Enfortumab vedotin with pembrolizumab significantly improved survival outcomes compared with chemotherapy in patients with previously untreated advanced urothelial cancer.

The FDA has approved inotuzumab for the treatment of pediatric patients 1 year or older with acute lymphoblastic leukemia.

Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.

Third-line combination of THIO and cemiplimab improved overall response rate compared with standard of care in patients with non-small cell lung cancer.

Balancing cost and efficiency remains at the crux of autologous stem cell transplants for multiple myeloma treatment.

The FDA orphan drug designation qualifies the sponsor of avutometinib for tax credits for clinical trials, exemption from user fees, and potential market exclusivity.

In an interview with Targeted Oncology, Chakra Chaulagain, MD, discussed the trends of higher rates of autologous hematopoietic stem cell transplantation refusal among patients with multiple myeloma.